Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aptose Bioscns
(NQ:
APTO
)
5.560
-0.110 (-1.94%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Jun 9, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
60,460
Open
5.610
Bid (Size)
5.400 (2)
Ask (Size)
7.000 (2)
Prev. Close
5.670
Today's Range
5.440 - 5.650
52wk Range
0.3600 - 6.600
Shares Outstanding
93,653,662
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Aptose Biosciences Provides Update on Reverse Stock Split
June 05, 2023
Common Shares to begin trading on adjusted basis June 6
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Hold Interim Clinical Update Webcast on Saturday, June 10, 2023
May 31, 2023
EHA Abstract on Tuspetinib and Venetoclax Recently Published
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Performance
YTD
+826.67%
+826.67%
1 Month
+1023.23%
+1023.23%
3 Month
+949.45%
+949.45%
6 Month
+694.29%
+694.29%
1 Year
+504.35%
+504.35%
More News
Read More
Aptose Enters into $25 Million Committed Equity Facility
May 25, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Analyst Expectations for Aptose Biosciences's Future
May 09, 2023
Via
Benzinga
Canaccord Genuity Maintains Buy Rating for Aptose Biosciences: Here's What You Need To Know
March 27, 2023
Via
Benzinga
Preview: Aptose Biosciences's Earnings
March 22, 2023
Via
Benzinga
Why Inovio Pharmaceuticals Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
May 24, 2023
Via
Benzinga
Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders
May 23, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
3 Stocks With 1,000% Upside Potential
May 21, 2023
Via
InvestorPlace
Aptose Reports Results for the First Quarter 2023
May 08, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Participate in RBC Capital Markets 2023 Global Healthcare Conference
May 04, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Report First Quarter 2023 Financial Results and Hold Conference Call on Monday, May 8, 2023
April 24, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Participate in Canaccord Genuity’s 2023 Horizons in Oncology Virtual Conference
April 10, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Biosciences to Participate in Cantor’s The Future of Oncology Virtual Symposium
March 28, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Reports Results for the Fourth Quarter and Full Year 2022
March 23, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Earnings Scheduled For March 23, 2023
March 23, 2023
Via
Benzinga
Aptose Reports Immaterial Financial Exposure to Silicon Valley Bank
March 10, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Report Fourth Quarter and Full Year 2022 Financial Results and Hold Conference Call on Thursday, March 23, 2023
March 09, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Biosciences to Present at Oppenheimer 33rd Annual Healthcare Conference
March 02, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
February 13, 2023
Via
InvestorPlace
Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia
January 30, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Biosciences to Present at Biotech Showcase™ 2023 Conference
December 28, 2022
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Why Aptevo Therapeutics Shares Are Trading Higher By More Than 100%; Here Are 28 Stocks Moving Premarket
December 12, 2022
Via
Benzinga
Aptose Biosciences Establishes New At-The-Market Facility
December 12, 2022
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations
December 11, 2022
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.